As a whole, the memory status of all combined myelin-specific CD8+ T cells in MS patients (52.2 ± 4.1%) was significantly increased compared to controls (40.5 ± 4.4%) (Fig. 2D). This evidence concerns the gene CD8A and myeloid sarcoma.